Greenwich Preclinical Trial Equipment Supplied In Texas

Following breast cancer surgery, a HER2/neu 3+ patient receives trastuzumab (Genentech/Roche’s Herceptin, a monoclonal antibody treatment that targets the HER2/neu protein) in the first year and then hopes that their breast cancer will not recur, with the odds of recurrence slowly decreasing over the first 5 years. Our immunotherapy, GP2, may be synergistic with Herceptin. GP2 is a nine ...